Welcome to our dedicated page for Absci news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci stock.
Absci Corporation (Nasdaq: ABSI) is a clinical-stage biopharmaceutical and biotechnology company that frequently issues news related to its generative AI-driven drug discovery platform and internal pipeline of biologic therapeutics. News coverage for Absci often centers on developments in its lead AI-designed antibody programs, platform collaborations, and corporate updates that are relevant to investors and the broader life sciences community.
A major focus of recent Absci news is ABS-201™, an anti-prolactin receptor (PRLR) antibody being developed for androgenetic alopecia and investigated for endometriosis. Press releases have described preclinical human ex vivo data on hair growth, the design and initiation of the Phase 1/2a HEADLINE trial in androgenetic alopecia, and plans for Phase 2 development in endometriosis. Updates also highlight scientific advisory board appointments, key opinion leader seminars, and partnerships aimed at elevating patient perspectives in hair loss research.
Investors following ABSI news can also expect announcements on pipeline progress for programs such as ABS-101, ABS-301, and ABS-501, as well as drug creation partnerships with pharmaceutical, biotech, technology, and academic organizations. Absci has reported collaborations with cloud and hardware providers to support its AI Drug Creation platform, along with participation in healthcare and biotech investor conferences and major industry events.
This news feed aggregates Absci’s press releases and third-party coverage, including items on clinical trial milestones, scientific data presentations, financing and capital markets activity, and corporate governance changes. Readers interested in ABSI can use this page to monitor how Absci’s AI-enabled platform, internal therapeutic programs, and partnerships evolve over time and to track key events that may shape the company’s scientific and business trajectory.
Absci (Nasdaq: ABSI) will host a virtual seminar on December 11, 2025 at 10:00 a.m. ET to discuss its ABS-201 (anti-PRLR) program for androgenetic alopecia with leading dermatology KOLs.
The company now expects to initiate the Phase 1/2a trial in early December 2025, ahead of prior guidance for early 2026, with an interim efficacy readout anticipated in the second half of 2026. The seminar will include presentations and a live Q&A; registration and archived webcast will be available at investors.absci.com.
Absci (NASDAQ:ABSI) has announced a strategic collaboration with Oracle Cloud Infrastructure (OCI) and AMD to enhance its AI-driven drug discovery platform. The partnership leverages OCI's AI infrastructure and AMD's latest hardware, including next-generation Instinct™ MI355X GPUs, to accelerate biologics design cycles and reduce costs.
The collaboration enables Absci to perform large-scale molecular-dynamics simulations and end-to-end antibody design with improved efficiency. Using OCI's bare metal instances powered by 5th Generation AMD EPYC™ processors, Absci has achieved ultra-low latency of 2.5 µs and terabytes-per-second throughput for data processing.
Absci (Nasdaq: ABSI) has strengthened its ABS-201 Scientific Advisory Board by adding two prominent dermatology experts, Dr. Rodney Sinclair and Dr. David Goldberg. The experts will guide the development of ABS-201, an AI-designed therapeutic antibody for androgenetic alopecia treatment.
ABS-201 targets prolactin receptors to stimulate hair follicle regeneration and has shown superior hair regrowth compared to minoxidil in preclinical mouse models. The company plans to initiate Phase 1/2a clinical trials in early 2026, with initial proof-of-concept data expected in H2 2026.
The condition affects approximately 80 million Americans, with current FDA-approved treatments showing limited efficacy and notable side effects. Both new advisors bring extensive experience in dermatology and hair loss research, with Dr. Sinclair having authored over 1,000 publications and Dr. Goldberg having participated in the original Minoxidil trials.
Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company focused on AI-driven therapeutic development, has announced its participation in three major upcoming investor conferences in September 2025.
The company will attend the 2025 Wells Fargo Healthcare Conference in Boston for one-on-one meetings on September 3, the Morgan Stanley 23rd Annual Global Healthcare Conference in New York for a fireside chat on September 8, and the H.C. Wainwright 27th Annual Global Investment Conference in New York for a fireside chat on September 9. Webcasts for the Morgan Stanley and H.C. Wainwright sessions will be available on Absci's investor relations website.
Absci Corporation (Nasdaq: ABSI) reported Q2 2025 financial results and business updates, highlighting significant developments in their clinical pipeline and financial position. The company successfully raised $64 million in gross proceeds in July 2025, extending their operational runway into H1 2028.
Key pipeline updates include the advancement of ABS-101 through clinical trials with an interim readout expected in H2 2025, and ABS-201 targeting Phase 1/2a initiation in early 2026. The company expanded its collaboration with Almirall, adding a second target for dermatological indications with potential milestone payments of up to $650 million.
Q2 2025 financial results showed revenue of $0.6 million (down from $1.3M in Q2 2024) and a net loss of $30.6 million (increased from $24.8M in Q2 2024). R&D expenses increased to $20.5 million, while SG&A expenses decreased to $8.5 million.
Absci (NASDAQ:ABSI) and Almirall (BME:ALM) have expanded their AI Drug Discovery collaboration by adding a second dermatology target. This expansion follows successful delivery of AI-designed antibody leads against the first difficult-to-drug target from their November 2023 collaboration.
The partnership combines Absci's Integrated Drug Creation™ platform with Almirall's dermatology expertise to develop novel therapeutics for skin diseases. Absci could receive up to $650 million in various milestone payments plus royalties, while being responsible for designing and validating therapeutic candidates. Almirall will lead preclinical and clinical development programs.
Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company focused on generative design for therapeutics, has scheduled its Q2 2025 earnings report and business update for August 12, 2025, after market close.
The company will host a conference call at 4:30 PM ET to discuss business developments, financial results, and future outlook. Investors can access the live webcast through Absci's investor relations website, with a replay available after the event.
Absci (Nasdaq: ABSI), a clinical-stage biopharmaceutical company focused on AI-designed therapeutics, has announced the pricing of its public offering of 16,670,000 common stock shares at $3.00 per share. The offering is expected to generate gross proceeds of approximately $50 million before deductions.
The company has granted underwriters a 30-day option to purchase up to 2,500,500 additional shares. The proceeds will fund internal program advancement, investment in their Integrated Drug Creation™ platform, and general corporate purposes. The offering, managed by Morgan Stanley, J.P. Morgan, Jefferies, and TD Cowen, is expected to close around July 25, 2025.
Absci (NASDAQ: ABSI), a clinical-stage biopharmaceutical company leveraging generative AI for therapeutic development, has announced a proposed public offering of $50 million in common stock. The company will also grant underwriters a 30-day option to purchase up to an additional $7.5 million in shares.
The offering will be managed by Morgan Stanley, J.P. Morgan, Jefferies, and TD Securities as joint book-running managers. Proceeds will support Absci's internal program development, platform investment, and general corporate purposes. The offering will be made through an effective shelf registration statement previously filed with the SEC.
Absci (NASDAQ: ABSI) has appointed Mary Szela, a veteran biopharmaceutical executive, to its Board of Directors. Szela, currently CEO of TriSalus Life Sciences, brings over three decades of experience, notably leading the global launch and expansion of Humira® at Abbott Laboratories.
Szela joins Absci as the company advances its AI-designed biologics pipeline, including ABS-101, an anti-TL1A antibody for IBD with Phase 1 data expected in 2025, and ABS-201 for androgenetic alopecia planned for clinical trials in early 2026. Her board experience includes Prometheus Biosciences (acquired by Merck for $10.8B), Kura Oncology, and Novo Nordisk.